JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A4139 AG-490
3 Citation

Target: EGFR|JAK

Summary: JAK2/EGFR inhibitor

insoluble in H2O; ≥14.7 mg/mL
A3320 CO-1686 (AVL-301)
1 Citation

Target: EGFR

Summary: EGFR inhibitor

≥27.8 mg/mL
A3433 Gefitinib hydrochloride

Target: EGFR

Summary: Potent EGFR inhibitor

insoluble in EtOH; ≥4.28 mg/mL
B1104 AZD-9291
1 Citation

Target: EGFR

Summary: Mutated forms EGFR inhibitor

≥24.98 mg/mL
B5836 AZ5104

Target: EGFR

Summary: EGFR inhibitor

insoluble in H2O; ≥16.95 mg/mL
A8357 AG-1478

Target: EGFR

Summary: EGFR inhibitor,potent and selective

insoluble in H2O; ≥15.8 mg/mL
A8366 ARRY-380

Target: HER2

Summary: Tyrosine kinase HER2 and p95-HER2 inhibitor

≥28.5 mg/mL
A8375 AZD8931 (Sapitinib)

Target: EGFR|ErbB

Summary: ErbB inhibitor

≥23.7 mg/mL
A8218 Lapatinib
2 Citation

Target: ErbB

Summary: EGFR/HER2 inhibitor,potent,selective and reversible

≥29.05 mg/mL
A8219 Gefitinib (ZD1839)
3 Citation

Target: EGFR

Summary: Selective EGFR inhibitor

≥22.34 mg/mL